Yike Medical Closes ￥100 Million Series A Financing

(VCBeat) July. 26, 2021 -- Hangzhou Yike Medical Technology Co., Ltd. ("Yike Medical") recently announced the closing of a Series A financing of nearly 100 million yuan. This round of financing was led by Shanghai Creation Investment, with participation from existing investors. Previously, Yike Medical had received tens of millions in angel round financing in September 2020.

According to the startup, proceeds from this round will mainly be used for new product research and development, the introduction of core equipment, talent recruitment. At the same time, the company will accelerate the product clinical trials and registration progress, and complete the comprehensive strategic layout of neural intervention products as soon as possible.

Yike Medical was founded on June 18, 2020 by a senior industry team at home and abroad, located in Binjiang High-tech Zone, Hangzhou. Currently, Yike Medical is mainly engaged in the development and industrialization of innovative neurointerventional medical devices and plans to develop more products in the field of pan vascular medicine in the future.

Jing Hongjuan, founder and CEO of Yike Medical, said, "At present, Yike Medical is focusing on the layout of neurointervention, and its product line mainly covers ischemic stroke treatment, hemorrhagic stroke treatment, and vascular access products."

Although founded only one year ago, Yike Medical has applied for more than 30 innovation patents, among which 5 patents have been authorized. In addition, the new device for stroke treatment developed by Yike Medical won the best project award at the 5th anniversary of The Chinese Cardiologists' Innovation Club (CCI) in 2020.

SCI, founded in 2006, is an international venture capital firm and investment bank focused on high tech and healthcare technology. Based in Shanghai, SCI has investments in Asia, the Middle East, and the United States. 

Over the last 10 years, SCI has successfully assisted more than 50 US/Israel/Chinese firms in private placement, M&A, or public offering. Raised a total amount of more than S1.25$ billion in private placement. In the healthcare domain, SCI works with a large network of more than 100 hospitals and  300+ doctors in China, the Middle East, and North America, in due diligence and clinical trials for SCI’s portfolio companies. The network also contributes significant help to industry researches.